LAUSR

The literature suggests a beneficial role of cholinomimetic agents in the treatment of pemphigus. In the present open‐label, prospective pilot study, we assessed the effectiveness of topical pilocarpine 2% eye‐drops in the treatment of recalcitrant oral lesions of pemphigus. A total of 20 patients with recalcitrant oral lesions of pemphigus were recruited and instructed to apply pilocarpine 2% eye‐drops twice daily on the resistant oral lesions for 180 days. The systemic immunosuppression at the time of inclusion in the present study was continued at the same dose throughout the study duration. The photographs of the lesions were obtained at baseline and an interval of 30 days. The area representing the erosion was measured on clinical photographs using the imageJ software (National Institute of Health). Visual analogue scale and oral health impact profile‐14 questionnaire were used to assess the degree of subjective improvement. Anti‐desmoglein 1 and 3, and anti‐acetylcholine receptor antibodies were measured both in serum and saliva; at baseline and at the completion of the study. A total of 20 patients were recruited in this pilot study. Mean total duration of illness was 3.4 ± 1.3 years. The mean area of the erosions decreased significantly from 142.01 ± 130.05 mm2 to 44.38 ± 67.78 mm2 at study completion at 180 days (p 0.002, paired t‐test). Repeated measures ANOVA demonstrated a significant trend in the reduction of the mean area of the erosions from baseline to day 180 (p 0.002). Mean VAS decreased significantly from 7.2 ± 1.0 at baseline to 5.1 ± 1.9 at day 180 (paired t‐test, p 0.001). Mean OHIP‐14 decreased significantly from 10.1 ± 2.7 at baseline to 8.4 ± 2.9 at day 180. No significant difference was observed between pre‐ and post‐treatment levels of anti‐desmoglein 1, anti‐desmoglein 3, and anti‐acetylcholine receptor antibodies, in both serum and saliva. The depth component in the erosions could not be measured. An orabase formulation could be used in future studies to facilitate retention of the medication at the site of application. Topical pilocarpine holds potential for the treatment of recalcitrant oral lesions of pemphigus vulgaris. It probably brings about re‐epithelialization without imparting any immunomodulatory activity.